Baseline characteristics of patients with cold agglutinin disease
| Patient . | Additional diagnosis . | Disease duration, y . | Age, y . | Sex . | Previous treatment . | Thromboembolic events . | Recent transfusion history . |
|---|---|---|---|---|---|---|---|
| C1001 | After LPL therapy | 4 | 70 | F | Steroids, bendamustine/rituximab | Venous thrombosis | 2 U 2014, 4 U 2015 |
| C1002 | 10 | 76 | F | Steroids, rituximab, IV immunoglobulins | None | 4 U 2014, 2 U before inclusion | |
| C1003 | LPL MYD88+ | 10 | 68 | F | Steroids | None | Never |
| C1004 | 1 | 74 | F | Steroids, erythropoietin previously and on study | Stroke | 4 U before inclusion | |
| C1006 | 4 | 70 | F | Steroids, azathioprine | None | 2-4 U monthly | |
| C1008 | 1 | 76 | F | Steroids, IV immunoglobulins | Pulmonary embolism | 4 U 2016 | |
| C1009 | LPL MYD88+ | 20 | 68 | M | None | None | Never |
| C1010 | After LPL therapy MYD88+ | 5 | 56 | F | R-CVP, rituximab, rituximab/fludarabine, eculizumab, R-ESHAP, erythropoietin (on study) | None | 4 U monthly |
| C1011 | Mixed AIHA (IgG+2) after LPL therapy | 12 | 76 | M | Cyclophosphamide, azathioprine, mycophenolate, rituximab, bendamustine/rituximab, eculizumab | None | 20 U 2015, 8 U 2016 |
| C1013 | Indolent* lymphoma | 3 | 59 | F | Steroids, rituximab | None | 7 U 2015 |
| Patient . | Additional diagnosis . | Disease duration, y . | Age, y . | Sex . | Previous treatment . | Thromboembolic events . | Recent transfusion history . |
|---|---|---|---|---|---|---|---|
| C1001 | After LPL therapy | 4 | 70 | F | Steroids, bendamustine/rituximab | Venous thrombosis | 2 U 2014, 4 U 2015 |
| C1002 | 10 | 76 | F | Steroids, rituximab, IV immunoglobulins | None | 4 U 2014, 2 U before inclusion | |
| C1003 | LPL MYD88+ | 10 | 68 | F | Steroids | None | Never |
| C1004 | 1 | 74 | F | Steroids, erythropoietin previously and on study | Stroke | 4 U before inclusion | |
| C1006 | 4 | 70 | F | Steroids, azathioprine | None | 2-4 U monthly | |
| C1008 | 1 | 76 | F | Steroids, IV immunoglobulins | Pulmonary embolism | 4 U 2016 | |
| C1009 | LPL MYD88+ | 20 | 68 | M | None | None | Never |
| C1010 | After LPL therapy MYD88+ | 5 | 56 | F | R-CVP, rituximab, rituximab/fludarabine, eculizumab, R-ESHAP, erythropoietin (on study) | None | 4 U monthly |
| C1011 | Mixed AIHA (IgG+2) after LPL therapy | 12 | 76 | M | Cyclophosphamide, azathioprine, mycophenolate, rituximab, bendamustine/rituximab, eculizumab | None | 20 U 2015, 8 U 2016 |
| C1013 | Indolent* lymphoma | 3 | 59 | F | Steroids, rituximab | None | 7 U 2015 |
Transfusions within 6 months of inclusion are presented in boldface.
F, female; LPL, lymphoplasmacytic lymphoma; M, male; R-CVP, rituximab with cyclophosphamide, vincristine, and prednisone; R-ESHAP, rituximab plus etoposide, cytarabine, cisplatin, and methylprednisolone; U, units of packed red blood cells.
CD19++, CD5–, CD10–, CD20+, CD22+, CD79b+, CD81+, FMC7+, partially CD38+, immunoglobulin M (IgM)+.